<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935674</url>
  </required_header>
  <id_info>
    <org_study_id>SOS</org_study_id>
    <nct_id>NCT01935674</nct_id>
  </id_info>
  <brief_title>Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels</brief_title>
  <acronym>SOS</acronym>
  <official_title>Rosuvastatin Versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of rosuvastatin to protease inhibitor switching on fasting total
      cholesterol over 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the effects of rosuvastatin to protease inhibitor switching on:

        -  Total cholesterol through week 12

        -  Safety parameters (HIV viral load, clinical adverse events, serious adverse events,
           laboratory adverse events, modifications to antiretroviral therapy)

        -  Quality of life (SF-12)

        -  Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides
           &gt;400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL
           cholesterol ratio, LDL particles sizes, triglycerides

        -  Fasting glucose and insulin

        -  Framingham cardiovascular risk score

        -  D:A:D 5-year estimated risk calculator
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in total cholesterol at 12 weeks.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol through week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters (HIV viral load, clinical adverse events, serious adverse events, laboratory adverse events, modifications to antiretroviral therapy)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-12)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides &gt;400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL cholesterol ratio, LDL particles sizes, triglycerides</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose and insulin.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham cardiovascular risk score.</measure>
    <time_frame>Screening and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D:A:D 5-year estimated risk calculator.</measure>
    <time_frame>Screening and week 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV</condition>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Switch ritonavir-boosted PI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue ritonavir-boosted PI+Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch ritonavir-boosted PI</intervention_name>
    <description>Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.</description>
    <arm_group_label>Switch ritonavir-boosted PI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continue Ritonavir-boosted PI+Rosuvastatin</intervention_name>
    <description>Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).</description>
    <arm_group_label>Continue ritonavir-boosted PI+Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-positive status

          -  Adults (≥18 years of age)

          -  Stable and well-tolerated combination ART including a ritonavir-boosted protease
             inhibitor for the previous 6 months

          -  HIV RNA &lt;50 copies/mL for at least the preceding 3 months

          -  Fasting total cholesterol ≥5.5 mmol/L (&gt;213 mg/dL)

          -  Framingham risk score ≥8% at 10 years OR diabetes mellitus OR a family history of
             premature coronary artery disease in a first-degree relative

          -  Provision of written, informed consent

        Exclusion criteria:

          -  Any statin in the previous 12 weeks

          -  Previous statin-induced myopathy or hepatitis

          -  History of coronary artery disease, stroke or any other indication for the use of
             statin therapy (hyperlipidaemia: genetic, secondary or idiopathic)

          -  Concurrent use of:

               1. oral corticosteroids use other than for replacement therapy (i.e. prednisolone
                  5-7.5 mg, hydrocortisone 20-30 mg, cortisone acetate 25-37.5 mg daily)

               2. other immunosuppressive or immunomodulating drugs

          -  Contraindication to rosuvastatin therapy:

               1. liver transaminases &gt;5 times the upper normal limit

               2. creatinine clearance &lt;30 mL/min

               3. known myopathy

               4. current fibrate therapy

               5. known resistance to one or more &quot;backbone&quot; ART drugs

          -  No potent switch ART drug available to replace the current ritonavir-boosted protease
             inhibitor

          -  Known intolerance to rosuvastatin or the proposed switch ART drug

          -  Women attempting or likely to become pregnant, or who are pregnant or breast-feeding

          -  A patient with a history or current evidence of any condition, therapy, or laboratory
             abnormality, or other circumstance that might confound the results of the study, or
             interfere with the patient's participation for the full duration of the study

          -  Unable to complete study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <keyword>Hypercholesterolaemia</keyword>
  <keyword>HIV</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Protease inhibitor switching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

